Coherus Oncology, Inc. (CHRS) Earnings Call Transcript
November 9, 2026
Earnings Call Speaker Segments
Thank you, Heidi. I'd like to welcome everyone to the conference call covering Coherus' earnings for the third quarter of 2026. With me on the line today are Denny Lanfear, our Chief Executive Officer at Coherus; Dr. Rosh Dias, who serves as Chief Medical Officer; Dr. Theresa LaVallee, our Chief Scientific and Development Officer; Sameer Goregaoker, Chief Commercial Officer; and Bryan McMichael, Chief Financial Officer. Before we begin, please be aware that this call contains forward-looking statements about what Coherus currently expects for future events. Those actual results could differ significantly, and we assume no obligation to update or revise any forward-looking statements. For additional detail on risks and uncertainties, please refer to the press release we issued today as well as our quarterly report on Form 10-Q. At this point, I'll hand things over to Denny.
Thank you, Carrie, and good afternoon to everyone. Thanks for being with us on the earnings call for our third quarter of 2026. Over the past few years we have worked to remake Coherus from a biosimilars business into an innovative oncology company whose focus is overcoming immune resistance in cancer. During that time we have made considerable headway cutting our debt, bringing operating expenses down, launching Loqtorzi in the market, and moving our clinical pipeline forward. We have run key clinical trials and generated enough data to determine the future direction of development for our tagmokitug program and to choose the dose we will take forward. I'd like to lay out three strategic paths aimed at positioning Coherus, by the end of 2027, as an oncology innovator that funds itself and delivers both best-in-class and first-in-class therapies. First, we're centering our strategy on esophageal cancer, making it the lead indication where tagmokitug can be best-in-disease. Second, there are structural and financial benefits that flow straight from that choice. And last, we're working to build Loqtorzi revenue across the next four or five quarters until it can cover the company's core cash burn on its own. When we launched the tagmokitug clinical program, our clear expectation was to select the most promising avenue for further development. That is exactly what we've now accomplished. As we announced on October 28th, during the last two years we have studied a broad range of mucosal system cancers, spanning head and neck, esophageal, gastric, and colorectal, in multiple lines of therapy, to learn where Treg depletion could best be taken forward as combination therapy. The data emerging from this highly systematic clinical investigation showed that esophageal cancer represents a best-in-disease opportunity in both first- and second-line therapy. So going forward, we will concentrate our tagmokitug development efforts sharply there, since this brings a substantial set of benefits. First, it gives patients facing a particularly difficult cancer with poor prognosis a treatment alternative. Second, our integrated approach spanning first- and second-line therapy will pursue FDA support for a rapid, efficient, and affordable development path that leads to accelerated approval. Third, it makes ex-U.S. partnering possible. Our encouraging interim data in combination with toripalimab, together with our development efforts now focused in this area, make it possible to hold partnering discussions for ex-U.S. rights. Toripalimab holds approval in Europe and other regions for treating ESCC regardless of PD-L1 status, and those markets are adopting it widely. Esophageal cancer ranks sixth worldwide in annual cancer deaths, with more than 400,000 patients affected each year, particularly in Asian countries. Our goals for ex-U.S. The benefits of partnering are threefold: first, those upfront payments can be used to offset clinical trial costs and to support accelerated approval strategies; second, partner funding for registration trials run outside the U.S. in their own territories substantially lowers the portion of total costs Coherus would otherwise carry; and third, leveraging global regulatory frameworks — FDA's Project Orbis being one example — to align approvals across regions so that all parties involved come out ahead; now that we have the data and clinical direction in hand, we are bringing on a financial advisor to conduct the tagmokitug partnering process, with particular attention to companies based in countries where esophageal cancer incidence is high. We'll keep you posted as things move forward. Now I'd like to discuss the structural and financial advantages stemming from our decision to make esophageal cancer the strategic priority. Across the last two to three years, we conducted a wide-ranging development effort covering multiple cohorts and indications—over 120 patients in total—so that we could determine which indication looked most promising and settle on the dose to move forward with. We have achieved both of those goals, and the dose and indication are now set for FDA conversations during 2027. Meanwhile, and in a somewhat lucky turn, two separate developments happening at the same time open up chances for us to right-size and cut costs. The first is our transfer of the toripalimab manufacturing process from China to the U.S. That wrapped up in the third quarter of 2026, and the FDA action date for the drug product side of the application falls on November 30th. As you might remember, the drug substance was cleared earlier in the year. Because of this, we can cut the continuing expenses tied to that transfer and approval, which had driven up our burn during the past two years. Next, our transition services agreement with Intas/Accord, the buyer of Udenyca, has largely run its course now, which lets us shrink our footprint further throughout the company. Those TSA efforts demanded a lot of manpower from us and artificially pushed up our cash burn, and they made things confusing for investors. These three developments coming together — setting our strategic priorities, phasing out the TSA, and the manufacturing transfer approval that's nearly here — give us a perfect chance to restructure and resize the company to match the narrower scope of what we're doing. So today we're announcing that we're carrying out an expected 30% cut in headcount, along with related expense savings. Bryan McMichael, our CFO, will go into more detail shortly. Let me share one important figure so you can see the benefits in context. The cuts we made by rightsizing and prioritizing add up to between $6 million and $7 million each quarter. As a result, the Loqtorzi revenue needed per quarter to cover the core burn drops from the $30 million to $35 million range we guided before, now to $25 million to $30 million. That puts us in a better position to build a sustainable operating model more readily, so we can keep putting money into our high-value clinical opportunities with more financial independence. Now let me turn to commercial and revenues. Sameer will give you more detail directly, but I'll summarize a few of the main growth drivers here. We're still making steady progress penetrating the NPC market, and our share right now is only about 20% to 22%. The takeaway here is that far too many patients are still receiving suboptimal treatment, and that represents a significant growth opportunity for us. Beyond that, since our market share remains fairly low, we tend to see volatility and unevenness from quarter to quarter whenever a region has an outsized fluctuation in patient numbers — discontinuations, for example. The remedy is to expand both share and penetration, which will smooth out those swings. There is still a considerable opening: approximately 30% of patients receive chemotherapy by itself, and those individuals are forgoing the Loqtorzi six-year survival benefit of 64.8 months compared with 33.7 months on chemotherapy alone. Within the coming year, we need to sharply reduce that 30% share by focusing closely on these patients and reaching their providers, who are then able to prescribe Loqtorzi alongside chemo according to our label. Given how compelling the survival data are, that objective appears reasonably achievable within the next 12 months; we also plan to address the 40% of patients receiving off-label immunotherapies that lack clinical evidence of efficacy — that share is declining steadily, though we need quicker progress on that front as well. Reaching and educating physicians is very important here, because HCPs recognize that we have superior data compared with chemotherapy alone in our standard of care. Over the past three quarters, we've advanced on this front, and Sameer will take you through both that progress and the approaches we're using to reach these physicians. Finally, our payer strategy is starting to deliver results, since the step edits now in place have shown themselves to be very effective at shifting long-standing prescribing habits. They compel physicians to pay attention, and we plan to extend this successful strategy into 2027. With that, I'll turn the call over to our Chief Medical Officer, Rosh Dias, MD. Rosh?
Thank you, Denny. I'd like to explain today why esophageal cancer has been chosen as the indication where we'll pursue future development using a best-in-disease strategy. Our plan is to run a second-line study in esophageal cancer covering both histologies — esophageal squamous cell carcinoma and esophageal adenocarcinoma — based on what we've reported from the Treg-Check 102 program. There are three reasons for this: first, how strong the signal is; second, the significant unmet medical need, especially in the second-line setting, where chemotherapy by itself remains the current standard of care; and third, the chance to move quickly toward the market by making use of FDA designations and development constructs. Let me begin with the second-line esophageal data and what we intend to do. In that setting, we showed activity in both the squamous and adeno histologies at the go-forward dose of 700 mg tagmokitug given with toripalimab. That covers nine evaluable second-line esophageal cancer patients — three adenocarcinomas and six squamous cell carcinomas. The overall response rate results were highly promising: we observed three confirmed PRs and one unconfirmed PR, which works out to a 33.3% confirmed ORR and a 44.4% ORR when unconfirmed plus confirmed responses are counted. That level of activity surpassed the benchmark for chemotherapy alone, which is roughly 10% ORR, in this area of high unmet medical need. In addition, the clinical benefit rate came in at 55.6%, with two patients still on treatment beyond five months and two more patients on treatment whose first tumor scan assessment has not yet taken place. Importantly, this was a randomized study across the two doses, with 22 patients treated to date; at the 300 mg tagmo dose combined with Tori, no responses occurred, and every patient had progressed by four months. Two key findings come out of this: first, the data indicate that toripalimab has limited activity in this second-line setting, which establishes contribution of effect; second, they give us confidence in 700 mg as the go-forward tagmo dose, since the activity clearly depends on dose. Very importantly, in terms of both response and duration, activity was seen in patients who are PD-1 refractory as well as in patients and tumors that are PD-L1 low or negative — meaning the tagmo-Tori doublet both overcame PD-1 resistance and showed activity in cold or PD-L1 low or negative tumors. Regardless of histology, these data shape our next steps and open the opportunity to advance our next study in second-line ESCC and second-line EAC, taking an approach similar to the one used in the pembrolizumab Phase 3 KEYNOTE-181 study. In our study, the tagmo-Tori doublet will be compared against chemotherapy. Our immediate next step is a meeting with the FDA to align on two topics: first, the recommended Phase 2 dose, so that we have satisfied the requirements of Project Optimus; and second, the design of the second-line esophageal cancer study and any potential for the data from this next study to support expedited development, including accelerated approval. Let me now walk you through the first-line setting interim data once again. For our first-line ESCC study, we ran a safety cohort aiming to enroll 12 patients treated with 700 mg of tagmo plus Tori and cisplatin/5-FU. In that group, we saw an overall response rate of 89%, and among PD-L1 positive patients the ORR reached 100%, which included one complete response — that works out to eight of the nine patients who were efficacy evaluable. Importantly, the activity appeared regardless of PD-L1 status. Durability also stands out, since two patients showed activity lasting nearly eight months. The safety profile proved manageable and acceptable. Four of the 10 safety evaluable patients did discontinue because of AEs, but that rate was similar to what CheckMate 648 reported, and half of those discontinuations stemmed from cisplatin-related renal toxicity; going forward, we intend to mitigate this by replacing cisplatin with oxaliplatin in the future study. As for the unmet medical need in first-line ESCC, three PD-1 chemo combinations hold FDA approval for first-line disease, and every one of them is limited to PD-L1 positive patients only, with ORRs spanning 44% to 59% among PD-L1 positive populations. Of course, keeping the usual caveats about cross-trial comparisons in mind, the fact that the tagmo-Tori chemo combination showed activity irrespective of PD-L1 status — and amounts to 100% in PD-L1 positive evaluable patients — speaks to the potential for improving on the current standard of care. Today's SOC for PD-L1 positive disease generally delivers a median PFS of roughly seven months, and while durability in this cohort is not yet mature, we look forward to continued follow-up for PFS. These impressive first-line data give us added confidence in the Treg mechanism across esophageal cancers. Our plan is to tackle the first-line ESCC opportunity once we advance the second-line, as part of our integrated development strategy and our commitment to the disease. To summarize, these data confirming tagmo's clinical activity, together with the strong pharmacology already established and previously communicated, support continued advancement, and concentrating on second-line disease in these esophageal histologies addresses an area of clear unmet medical need, where a chemo-free option would be greatly appreciated by patients. With that, I'll hand over to Sameer. Sameer?
Thank you, Rosh. Net sales for the third quarter came in at $14 million, which reflects 3% growth over the prior quarter and 25% growth compared with a year ago. Sequential growth came in below the 10% to 15% target we had set, and the reason was slower starts of new patients in a handful of territories, but the fundamental drivers behind long-term growth are still stable. At the national level, growth in accounts buying Loqtorzi for the first time matched what we saw in the second quarter. Discontinuation rates among patients also aligned with earlier quarters, and the length of treatment kept rising steadily. After a thorough assessment, our view is that demand fundamentals are strong and that patient flows localized to certain territories held growth back this quarter. Over the long term, we aim to hold a dominant share of the NPC market by displacing suboptimal chemotherapy-only regimens and off-label I-Os. We have invested substantially to reach these goals. Given how rare NPC is and how patient flow behaves, these efforts will require time. That said, recent market research showed positive leading demand indicators along with strong physician sentiment; we surveyed academic and community oncologists alike to gauge how they perceive Loqtorzi and to help shape our view of future demand. The findings were encouraging. In our survey of oncologists, 75% currently regard Loqtorzi as the standard of care for NPC, whereas under 35% feel the same way about off-label I-Os. Since the prior survey in early 2026, this represents a meaningful positive change in sentiment regarding Loqtorzi. Our view is that the shift is being propelled by focused promotional efforts around the Loqtorzi superiority narrative. Furthermore, 57% of oncologists now know about our six-year overall survival data. As a reminder, that data demonstrated nearly double the survival with Loqtorzi plus chemotherapy compared with chemotherapy by itself. We are glad to have reached this awareness level within three quarters of the data becoming available. To convert those positive physician impressions into faster uptake, we have three priorities. First, our field team continues to concentrate on claims-based alerts that help spot physicians prescribing chemotherapy by itself. Roughly one-third of eligible patients are still getting chemo alone, and our education work aims to reduce this less-than-ideal treatment. Second, we are now working with large clinical organizations to find patients who are not receiving Loqtorzi according to the label and the NCCN guidelines. We then educate physicians inside those partner organizations about Loqtorzi's superior survival benefits. Third, we are teaming up with major national and regional payers so that Loqtorzi becomes the preferred option for eligible NPC patients. In areas where those payer partnerships already exist, the portion of addressable patients we capture runs at roughly twice the national figure. We're currently broadening these payer relationships, aiming to reach most covered lives in the U.S.; our earlier guidance called for a $15 million quarter during 2026, and we anticipate hitting that target in Q4. Over the longer horizon, we still expect to arrive at peak market share by 2028, in line with what we projected before. With that, I'll turn it over to Bryan McMichael, our Chief Financial Officer.
Thanks, Sameer. I'll begin today by covering Coherus' liquidity, how we plan to manage cash burn, and what the organizational rightsizing announced today gives us — including the cost cuts and the savings we expect. As of the close of Q3 2026, cash, cash equivalents, and investments stood at $83.6 million, a drop of $21.7 million from $105.3 million at the end of Q2; that move mirrors an anticipated decline in cash burn. Cash used in operations during Q3 came to $34 million, a 43% decrease versus the quarterly average across the first half of 2026. As we indicated on the prior earnings call, the main driver of the slower burn was a substantial decrease in cash spent paying down TSA payables and accrued liabilities tied to the biosimilar business we divested. As previously announced, in Q3 we retired our $38.7 million term loan with proceeds from a new $55 million term loan that closed in the quarter; that refinancing added a net $11.5 million of cash to the balance sheet. As Denny described, this strategic prioritization will produce meaningful benefits that further lower burn. Once in place, we anticipate a sustainable cut in recurring costs averaging $6 to $7 million per quarter, and we expect to reach most of that savings rate within two quarters. Those savings will stem mainly from a roughly 30% headcount reduction, from about 140 to 100 FTEs, which happens this month. Although these cuts span the organization, we are keeping substantially all of the commercial organization intact as we focus on growing Loqtorzi sales. In line with our strategic prioritization, we intend to realize savings by deprioritizing certain tagmokitug indications. Once carried out successfully, these steps would help extend cash runway and lower ongoing core costs, which include all non-cash costs of the business apart from development costs. That brings down the quarterly Loqtorzi revenues needed to cover those core costs from the $30 to $35 million we guided previously to $25 to $30 million per quarter. Coherus recently obtained the revenue report tied to the Udenyca divestiture. Reaching the earnout threshold for the first $37.5 million milestone would require only a modest audit adjustment, since reported net sales came very close to hitting that threshold in the first earnout period. As the purchase agreement allows, we are exercising our audit rights and other contractual rights, and we will review the reported results thoroughly. As a reminder, the report on the second $37.5 million milestone will come after Q1 2027. Without factoring in possible benefit from the cost reductions, the milestone payment, or proceeds from ex-U.S. deals, our cash runway is under 12 months from the date of the 10-Q we filed today. Accordingly, that quarterly report contained going concern disclosures to reflect this; on the expense side, we delivered another strong quarter of cost reduction compared with the same quarter a year earlier. Sameer already walked through this, but to recap: Loqtorzi brought in $14 million, which was a 3% increase quarter over quarter. We're still confident in where Loqtorzi can go longer term, but this quarter's unevenness came in larger than we'd expected, so we're adjusting our full-year revenue guidance range down to $54 million to $57 million. Now on the expense side. R&D expense from continuing operations came to $22.6 million in Q3 2026, versus $27.3 million in Q3 of last year. That drop mostly reflects fewer people on staff, reduced infrastructure spending, and lower costs for clinical trials and R&D manufacturing. SG&A from continuing operations landed at $21.2 million in the third quarter, compared with $24.9 million in Q3 2025. Those savings mainly came from a smaller headcount and reduced operating costs tied to Coherus fully exiting the biosimilar business during 2025. Looking at full year 2026, we're reaffirming our expectation for combined opex in the $170 million to $175 million range; with that, I'll turn things back to Denny.
Thanks, Bryan. I'll start by recapping where we stand with tagmokitug, our molecule, and after that I'll walk you through the strategic plan. What we've demonstrated at this point is that we have the correct drug, aimed at the correct target, in the correct disease, and that it can move forward into development for esophageal cancer. In the first-line setting, these data go beyond established benchmarks and build on the chemo-I-O combinations currently available, while in second-line they meet a substantial unmet need through a chemo-free option. Worldwide, esophageal cancer ranks as the sixth deadliest malignancy, and in the U.S. roughly 18,000 new cases are diagnosed annually, with 16,000 deaths from the disease each year. Our near-term steps are as follows: first, continue conversations with interested parties in the U.S. as well as outside it — those discussions are now getting underway. Second, reach alignment with the FDA on dose, on trials, and on the development strategy, including pathways and options for expedited development. Turning to strategic prioritization, as Bryan laid out, we are rightsizing the company so that it matches our sharper focus, and that lowers our costs. We intend to push commercial sales toward core burn breakeven as fast as we can, targeting 2027. We will also seek non-dilutive funding, which includes partnering deals outside the U.S. Operator, we're ready to take questions.
Oh, great. Thanks so much. I appreciate all the detail provided on the call today. Regarding tagmo, could you elaborate a bit on how you're viewing the possible regulatory pathway in the second-line setting? Is this a trial where you might use PFS or even ORR as an interim endpoint for accelerated approval within a Phase 3? How strong is the precedent for combining esophageal squamous cell carcinoma with EAC in this setting? Thanks.
Thank you. Thank you, Paul. I'll have Dr. LaVallee, our Chief Development and Regulatory Officer, address that. Theresa?
Hi Paul, thank you. Yes, a clear path exists, and this is something people do routinely. A lot of the pembro trials enrolled patients from both histologies. The FDA treats esophageal cancer with two histologies as a single disease — there's solid precedent, and KEYNOTE-181 is the most notable and the closest match. Second, the FDA has demonstrated, including through the recent approval of origami 4, an accelerated approval granted last week, that ORR/BICR combined with durability is an endpoint open to discussion. That's the approach we intend to bring to them: a plan showing a randomized trial against chemotherapy, which is the sole agent available for these patients, especially in the PD-1 refractory or PD-L1 low population, and to discuss accelerated approval on that basis, along with what the confirmatory study would look like — whether a seamless design or a separate second trial.
Thank you, Paul. Did you have a follow-up question?
Yeah, just a quick follow-up. You clearly had really compelling data in the frontline setting too. I'm just curious how you're thinking about the gating factor for starting a frontline study. Could that be done in parallel with the second-line study, maybe somewhat staggered, or would it really depend on first having a positive outcome in the second-line setting?
Great question. Theresa?
Both of those initiatives can definitely move forward at the same time, and the FDA would be keen on it—they favor seeing dedication to the disease, especially with their Project FrontRunner push toward earlier-stage work. Of course, we've put second-line first because of how complicated it is to isolate the contribution of effect in first-line, plus the first-line study's size and duration, but since toripalimab has already shown activity in that disease and we aim to bring immunotherapy into earlier lines, we'll keep looking for ways to develop and gather additional data in that disease type.
Okay. Thank you very much.
Thank you, Paul.
Hi there. Congratulations on the sharper new focus, and I appreciate you fielding the question. Perhaps to build on the frontline opportunity point — bearing in mind that second-line ESCC is your priority — you had 8 of 9 confirmed responses in the frontline, and I believe I caught you saying that you'd keep growing that data set. Could you discuss what level of evidence would be needed to keep that frontline opportunity alive and move it ahead? Then, if I may ask one follow-up on the financial side, starting from the current $14 million quarterly base for Loqtorzi, what commercial pushes and pulls might give you the leverage required to reach the new $25 to $30 million quarterly Loqtorzi revenue threshold? Thank you.
Thanks, Jay. I'll have Dr. LaVallee address the frontline question and your sharp observation that 8 out of 9 patients responded — quite an impressive response rate. Theresa, why don't you take that, and then Sameer will follow up on the $14 million. Go ahead.
To move forward with another discussion with the FDA on the first-line setting, I believe three elements are needed. First, we have to complete enrollment. On ORR — I know we all like that early readout — but I regularly remind people that durability, CBR, and PFS matter. We're glad to see it moving in the right direction, yet bringing only ORR to the FDA in a frontline study wouldn't produce the most useful conversation. With 22 patients in the second-line study and randomized data in hand, we can have a productive and robust dialogue about advancing development, especially on an expedited basis. Naturally, we wouldn't pass up the chance in a meeting to explore first-line possibilities and learn their thinking while we generate additional data there, including durability.
Thanks, Jay. Sameer will speak to the matter of climbing above that $14 million figure, and to the pushes and pulls you mentioned—what it takes to lift it, at minimum beyond the $15 million we're forecasting for the coming quarter. Sameer?
Thank you, Jay, for that question. Clearly, our near-term objective is to beat $15 million for the guidance, but even more important over the longer term is maximizing the opportunity. As Denny said, there's substantial upside for this brand. If there's excessive chemotherapy by itself happening — roughly 30% of patients receive chemotherapy alone — and excessive Keytruda plus off-label I-Os happening. So what are we doing about that? We have significant, strong physician support helping us drive Loqtorzi utilization. What stands in the way is typical rare disease dynamics and patient flows, which are comparatively slow. Then another obstacle is simply habit. Far too many physicians agree to use Loqtorzi, yet six months later, when the patient arrives, they forget to use Loqtorzi. Our response is twofold: our representatives are driving it from the bottom up, educating physicians; and we're also pursuing two main initiatives: we're working directly with large clinical organizations and large academic centers, working from the top down to identify patients and get them on Loqtorzi. The second thing we're doing is partnering with payer organizations to establish preference among payers for Loqtorzi for utilization for label. Once those two steps are in place, we believe we can accelerate demand in the coming quarters.
I'd just like to add, Jay, that we hold roughly 22% of the market — between 20% and 22%. There's plenty of room for growth; we certainly need to make inroads into that 30% for chemo-only patients, and beyond that, 40% in other I-O is something we must go after as well. Our view is that growth will come from the step-throughs. On the other point Sameer raised a moment ago, it matters a great deal in the community that those chemo-only patients be switched to chemo plus Loqtorzi, so that they receive the full benefits of the six-year survival. What we've seen is that they respond very receptively when we discuss this with them.
That's really useful. Thanks.
Hello, and thanks for taking the questions. I've got two. The first concerns tagmokitug, more specifically its pairing with pasritamig. Did any patients receive that combination, and if none did, will it be dropped before it begins? I'm asking because —
Mike, hang on a moment with that one. I'll address it first, then Rosh will handle that, and after that we'll move on to your second question. Rosh, go ahead. Sure,
Sure.
Hi, Mike. It's nice to talk with you. Regarding the pasri study, we've actually already gotten that one underway — a few sites have started it and are screening patients now, so that remains a priority we're pushing forward. What matters here is that this is being done alongside the T-cell engager, so again, as we've discussed, it's first-in-disease, first in combination with the T-cell engager, and yes, we're moving that ahead.
Regarding that, Mike, I find it quite interesting. Dr. LaVallee might have more to say about the remodeling of the tumor microenvironment and some other observations we've made, and how that could relate to additional TCE efforts. Theresa, would you like to weigh in?
Yes, the information we've provided about the Treg-Check program demonstrates that eliminating the immune suppressor cells, drawing the CD8s in, and truly boosting an immune response has been shown. A T-cell engager combination is something I'm especially enthusiastic about, since the obstacle to the size of benefit from those agents has been a shortage of T cells along with the Tregs being present; that has us incredibly excited. It was exciting to see on Saturday that J&J presented combination data with pasri and their PSMA-CD28 showing really good safety and a capacity to potentiate the PSA response; we have our benchmarks, and we look forward to a few days of dosing patients in this combination.
Theresa, if the safety profile holds up for pasritamig in prostate, what does that suggest for other TCE studies of a similar kind?
I think I'll be very, very busy with looking at all the options.
Mike, did you have a follow-on question?
Great. No, that covers it. We'll be looking forward to hopefully getting some data from that cohort at some point down the road. My next question is actually about casdozokitug. I suppose I was just wondering whether you could clarify something. My assumption is that it isn't being deprioritized as such — presumably you're waiting on the HCC data before you make a go/no-go call. If that's correct, could you tell us what benchmark you have in mind for supporting continued investment in casdozo?
I can take the first part of that, and then I'll let Dr. Dias take the second part. No, no, no. Casdozokitug has not been deprioritized. It's maturing nicely. I believe we've said recently that it has shown, I think, very strong dose-response differentiation. The point is that the response is maturing, and so we'll probably have some additional insights into how that's progressing and have more to say about it sometime in Q1, in the early part of the year. It's simply taking time for it to develop a bit. When you're in a situation where fewer than half the patients have a sufficient number of scans, you just have to wait. As for the benchmarks, I'll let Dr. Dias address that. Rosh?
Mike. Two quick points from me. First, I want to restate that what we have observed up to now with casdozo is activity that depends on dose. Second, this kind of data needs a bit of time before it matures. You may remember from the earlier trial of ours, casdozo-atezo-bev, that in the first dataset we reported an ORR of 27%, and as time passed that figure rose to 38%; on top of that, there were zero CRs in that initial cut, and by the final cut that number had climbed to five CRs. We expect a comparable pattern in the study we are running now. If the initial ORR we see lines up with our earlier data, I think we would be pleased, since the key thing is that this data has to mature, deepen, and rise over time. At a minimum, that is what we hoped to find in our first study. And naturally, the safety profile is consistent, and it was very consistent with what atezo-bev showed on its own previously.
Great.
Thanks, Mike.
Hello, and thank you for taking my question. Charles here, speaking on behalf of RK. So perhaps for me, what exactly is it about the second-line esophageal cancer setting that makes it the quickest route to market? When do you anticipate holding the meeting with the FDA, and as things stand, what have you talked about with the FDA regarding this program? Thanks.
Those are all excellent questions, Charles. Dr. LaVallee, would you be able to speak to those two points — why second-line is the fastest, and where things stand with the FDA?
Second-line esophageal cancer is plainly an area of substantial unmet need. Looking at the latest approval for second-line ESCC involving tislelizumab, and if you go through the FDA's remarks on that approval, they return again and again to how underserved this population is. One objection raised in that approval package was that testing had not been done in PD-1 refractory disease, and since PD-1 was already established, availability for any patient in the U.S. would be limited. Because of the unmet need, it will still secure approval. Simply from reading their characterizations of their view of this disease, in second-line EAC essentially nothing has been approved. Chemotherapy is what these patients can choose. They are plainly very ill. As our study showed, median overall survival among this population comes to roughly 8 months. When it comes to pursuing a compelling signal where we have demonstrated contribution of effect, we have 22 patients in the randomized study with an ORR, and notably, a number of patients with stable disease at about 8 months on treatment. That supports a dialogue, and also the powering of a trial for what we would need to observe in a randomized study to genuinely move ahead with the FDA on regulatory pathways. That keeps it streamlined and fast. We know the drugs, and we can speak to contribution of effect. We held a Type B meeting with FDA to get aligned on our Project Optimus randomized cohorts that we just presented. The following 2 meetings my team is working on right away and intends to hold with the FDA early in 2027 are, first, to get the recommended Phase 2 dose finalized, and second, a Type B meeting to talk over development in esophageal cancer.
We're seeing activity in both histologies—squamous as well as adeno—among patients who are progressing very rapidly, a population with unmet need where there's no real therapy apart from chemotherapy, and that speaks to our ability to make a genuinely positive impact on these patients' lives.
There's one more point I want to make, since there's plenty of discussion out there about how this applies to U.S. medical practice: our study does include U.S. patients, and U.S. patients are among those who benefited. That, I believe, positions us well to satisfy many of the FDA's requests regarding how to proceed in this disease.
Thanks, Charles.
Good. Appreciate you taking my questions.
Hi, everyone. Thanks for fielding what we have to ask this afternoon. To add to what was just asked, when we consider the faster development route in second-line ESCC for tagmo and Tori, what's the right way to think about how a study might be set up? I know, Theresa, that you mentioned KEYNOTE-181 as a comparable. Is that a reasonable benchmark for considering an accelerated trial here, and could you also give any detail on the type of response metric and the study size that would be required? Thank you.
Hi, Brian. Thanks. Theresa, would you like to handle that one for Brian?
The following trial on our agenda is a randomized one versus chemotherapy, encompassing both histologies and examining PD-L1 subtypes across the board—which is precisely what we'd like to sharpen together with them as a Phase 2 effort, with a shot at accelerated approval based on BICR ORR, that is blinded independent central review ORR, over a duration of six months. As things stand, chemotherapy sits at 10%, and regarding the six months, as we mentioned, median OS comes in at roughly eight months, so six months looks quite robust. In my view, doubling that figure, or even tripling it, would be sufficient, but those are the discussions we'll be having, and I'll be in a position to respond in specific terms after an FDA conversation.
Theresa, for Brian’s benefit, when do you expect those discussions to take place? When do you think the package will be submitted, and when do you think we’ll have something to say?
We're pushing hard on that to get the meeting set for the first quarter. Obviously, if we submit at the close of this year or the start of next, with that 60-day clock, it points to a March time frame—that's what we're targeting. On KEYNOTE-181, I'd like to highlight a couple of points: that one is a Phase 3. KEYNOTE-590, the first-line esophageal study, also combined histologies, which isn't unusual. But 181 did fail in the PD-L1 below 10 group and also failed in the EAC histology. We aren't aiming to replicate that study; our goal is to move past it and also treat patients whose disease has progressed on frontline immunotherapy, which has been commonly done and accepted by FDA across multiple lines of treatment.
Thanks, Brian.
I appreciate the context.
Thank you, Heidi. I want to thank everyone for being with us on today's Q3 call. Tomorrow we'll be at Guggenheim, so we'll see you there, and we'll see you as well at Jefferies in London. Thanks.
This concludes today's conference call. Thank you for participating. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Coherus Oncology, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Coherus Oncology, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.